PUBLIC DISCLOSURE OF DISPOSITION OF ANTI-DOPING MATTER UNDER RULE 14.3.2 - PAUL KIPCHUMBA LONYANGATA (KEN)

1. On 24 September 2021, Paul Kipchumba Lonyangata1 (“the Athlete”) provided a Sample Out-of-Competition during a Doping Control conducted by the Athletics Integrity Unit (“AIU”) on behalf of World Athletics, which resulted in an Adverse Analytical Finding for Furosemide2 (“the AAF”) which is a Specified substance, prohibited at all times.

2. On 19 October 2021, the AIU notified the Athlete of the AAF.

3. On 26 October 2021, the Athlete admitted the Anti-Doping Rule Violations (“ADRVs”) pursuant to Rule 2.1 and Rule 2.2 of the World Athletics Anti-Doping Rules (“ADR”).

4. The AIU, the Athlete and the World Anti-Doping Agency subsequently entered into a Case Resolution Agreement in accordance with Rule 10.8.2 ADR pursuant to which:

4.1. the Athlete acknowledges to have committed ADRV under Rule 2.1 and 2.2 of the ADR;

4.2. the Athlete agrees to be sanctioned for the ADRV with a period of Ineligibility of nineteen (19) months pursuant to Rule 10.6.1(a) of the ADR;

4.3. taking into consideration that the Athlete promptly admitted the ADRs upon notification, the period of Ineligibility commences on the date of admission on 26 October 2021 and shall be in effect until, and including, 25 May 2023; and

4.4. in accordance with Rule 10.10 of the ADR, the Athlete’s competitive results from 24 September 2021 are disqualified with all resulting consequences, including forfeiture of any medals, points and prize money/prizes.

5. Following the Case Resolution Agreement, there is no right of appeal in the matter under the ADR and the disposition of the Athlete’s case is published in accordance with Rule 14.3.2 ADR.

Monaco, 11 February 2022

1 https://worldathletics.org/athletes/kenya/paul-lonyangata-14425821

2 Furosemide is a is a Prohibited Substance under the WADA 2021 Prohibited List under the category S5: Diuretics and Masking Agents.